An impressive response to pazopanib in a patient with metastatic endometrial carcinoma.
Neth J Med
; 74(9): 410-413, 2016 Nov.
Article
em En
| MEDLINE
| ID: mdl-27905309
ABSTRACT
The incidence of endometrial carcinoma is rising and the patients with distant metastases have a poor prognosis, especially when progression of disease occurs after systemic treatment with hormonal therapy or chemotherapy. Pazopanib, a multi-targeted inhibitor of several oncogenic receptor tyrosine kinases, has been investigated in patients with chemotherapy-resistant endometrial carcinoma or patients for whom chemotherapy is contraindicated. In this report we will describe a spectacular response to pazopanib in a patient with recurrent metastatic endometrial carcinoma.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pirimidinas
/
Neoplasias de Tecidos Moles
/
Sulfonamidas
/
Neoplasias do Endométrio
/
Carcinoma Endometrioide
/
Inibidores da Angiogênese
/
Parede Abdominal
Tipo de estudo:
Prognostic_studies
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Neth J Med
Ano de publicação:
2016
Tipo de documento:
Article